Disappointing phase I results halt Novo's Dutch acquisition
![](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article10987525.ece/ALTERNATES/schema-16_9/novo-bioeurope.jpg)
Dutch company Staten Biotechnology retains its independence as Novo Nordisk has decided not to exercise an option to acquire both the company and its lead candidate, STT-5058, the Danish pharmaceutical company reports in its financial report on Wednesday.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.